

Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke: Association with mortality and cardioembolic etiology

Neurology® 2018;91:637. doi:10.1212/WNL.00000000000005190

In the article “Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke: Association with mortality and cardioembolic etiology” by G.M. De Marchis et al.,¹ the version published ahead of print on January 10, 2018, contained some errors. The sixth sentence of the Abstract should specify “*continuous* net reclassification index (cNRI),” and the ninth sentence should report the significance of cNRI of atrial fibrillation at (78%, 95% CI 60%–89%, $p < 0.001$). In the Results section, the third sentence has been changed to “The median age of the cohort was 71 (IQR 61–80) years, and 298 (38%) were *women*.” Under the subsection “Prediction of functional outcome after 3 months,” the first sentence of the second paragraph should report “(AUC change from 0.85 [95% CI 0.83–0.88] to 0.86 [95% CI 0.83–0.88], $p < 0.0071$).” The last sentence of the Results section should specify “...a *continuous* NRI of 78%.” The title for table 2 should read, “Multivariate logistic *and* Cox regression analyses for 90-day functional outcome and mortality WITH and WITHOUT MR-proANP.” In table 4, the number (n) and percentage (%) values were reversed from row 3 through row 12, and in table 5, row 7 should have a p value of 0.35 (for dyslipidemia), rather than 0.035 as originally published. Corrected text and tables were published in the final version on February 6, 2018. The authors regret the errors.

Reference

1. De Marchis GM, Schneider J, Weck A, et al. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke: association with mortality and cardioembolic etiology. *Neurology* 2018;90:e455–e465.

Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production

Neurology® 2018;91:637. doi:10.1212/WNL.00000000000005979

In the article “Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production” by J.S. Charleston et al.,¹ the Acknowledgment is incomplete. It should also include “The authors also gratefully acknowledge Dr. Steven A. Moore, the University of Iowa Hospitals and Clinics Histology Laboratory, and the Iowa Wellstone Muscular Dystrophy Cooperative Research Center (NIH grant U54, NS053672) for providing frozen sections of non-dystrophic control muscle biopsies, Becker muscular dystrophy muscle biopsies, and untreated DMD biopsy samples from the PROMOVI clinical study described in this manuscript. Dr. Moore also assisted in establishing criteria for defining dystrophin positive muscle fibers.” The authors regret the omission.

Reference

1. Charleston JS, Schnell FJ, Dworzak J, et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. *Neurology* 2018;90:e2146–e2154.

Neurology®

Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production

Neurology 2018;91;637

DOI 10.1212/WNL.0000000000005979

This information is current as of September 24, 2018

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/91/13/637.2.full
References	This article cites 1 articles, 1 of which you can access for free at: http://n.neurology.org/content/91/13/637.2.full#ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

